NEW YORK, July 1 - CombiMatrix generated $5.8 million in cash payments for the second quarter, the company's parent, Acacia Research, said today.
CombiMatrix has a semiconductor-based microarray technology, which it is marketing and using to develop siRNA compounds that target common viral diseases.
The Squolamie, Wash., company did not specify the source of CombiMatrix's revenues, but CombiMatrix CEO Amit Kumar did mention the company's collaboration with Roche, its strategic alliance with Toppan, and the launch of the siRNA drug discovery program, Express Track.